• Juan Miguel Redondo, Miguel Ángel del Pozo, Mercedes Ricote, Vicente Andrés and Francisco Sánchez-Madrid (CNIC, Madrid)

• Domingo F. Barber (Centro Nacional de Biotecnología, Madrid)

• Ziad Mallat (Paris Cardiovascular Research Centre, France)

• Laurence Zitvogel and Guido Kroemer (Institut Gustave Roussy, Villejuif, France)

• Jurgen Ruland (Technische Universität München, Germany)

• Caetano Reis e Sousa (London Research Institute, Cancer Research UK)

• Sho Yamasaki (Medical Institute of Bioregulation, Kyushu University, Fukukoa, Japan)

• David Sancho Madrid
• Junior group leader
• Ext.2010

David Sancho graduated in Biology at the University of Murcia, Spain (1995) and pursued a research career while specializing in Immunology through the Spanish National Health System program at the Hospital de la Princesa, Madrid (2000). The subject of his PhD thesis (Universidad Autónoma de Madrid, 2003) was the function of the C-type lectin CD69, with special emphasis on models of inflammation. During his postdoc tenure at the London Research Institute, (Cancer Research UK, 2004-2009) he discovered a new C-type lectin receptor specific to dendritic cells (CLEC9A, DNGR-1) that was subsequently used for targeted anti-tumor vaccination. Through the generation of CLEC9A deficient mice, he found that this receptor is involved in the generation of immunity associated with dead cells. This work has possible implications in the origins of chronic inflammation and autoimmunity. He joined the CNIC in September 2009.